Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/ neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

Bispecific antibody (bsAb)-based clinical trials of cancer have been conducted primarily using intact murine monoclonal antibody (mAb)-derived molecules. In some of these trials, toxicity resulting from the interactions of antibody Fc domains with cellular Fc receptors has limited the doses of antib...

Ausführliche Beschreibung